NEW YORK (GenomeWeb News) – LabCorp has obtained an exclusive license granting it access to MGMT methylation-related IP technology developed by the molecular diagnostics company OncoMethylome Sciences, the companies announced today.

The move will allow LabCorp to do commercial MGMT methylation laboratory testing in the US and Canada, with limited exceptions. OncoMethylome also named LabCorp’s Esoterix Clinical Trials Services Division as one of its preferred subcontractors for clinical trial MGMT methylation testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.